{"id":"W3035208766","doi":"10.1158/1078-0432.ccr-20-0621","title":"Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":172,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Sierra Oncology; Australian Government; Eisai; BeiGene; Sanofi; Clovis Oncology; AstraZeneca; Bristol-Myers Squibb; Amgen","keywords":"Nivolumab; Ipilimumab; Medicine; Clinical endpoint; Internal medicine; Clinical trial; Response Evaluation Criteria in Solid Tumors; Progressive disease; Neuroendocrine tumors; Immunotherapy; Gastroenterology; Oncology; Phases of clinical research; Surgery; Cancer; Chemotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003385901,0.001093054,0.002711587,0.0005306165,0.0003814962,0.001039803,0.0005052824,0.0008404063,0.00155813],"category_scores_gemma":[0.002417078,0.0003237944,0.005570142,0.0006379411,0.0003848592,0.0004697536,0.000483518,0.001024547,0.0002744908],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008629983,"about_ca_system_score_gemma":0.001020177,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008704524,"about_ca_topic_score_gemma":0.002517914,"domain_scores_codex":[0.9980904,0.001007152,0.0002558498,0.0002843761,0.0001558056,0.0002064062],"domain_scores_gemma":[0.9985374,0.0004394266,0.0003511564,0.0002758094,0.0001159645,0.0002802941],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8114825,0.001951861,0.09950923,0.001153211,0.03570523,0.0005130857,0.0002140734,0.001655378,0.01061917,0.000176548,0.002312678,0.03470707],"study_design_scores_gemma":[0.3999636,0.1087045,0.4029199,0.0003566529,0.06585564,0.001733554,0.0005579866,0.005863204,0.004259267,0.00120549,0.008388038,0.0001921155],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9916285,0.005770241,0.0002555638,0.0002492079,0.0001047653,0.0005106632,0.0006670755,0.00001959127,0.0007943815],"genre_scores_gemma":[0.9975262,0.0005403818,0.0002079846,0.0002245877,0.0001012406,0.0002901418,0.0008062004,0.000009483932,0.0002937321],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003385901,"threshold_uncertainty_score":0.01790655,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1458014106400074,"score_gpt":0.4961921606803399,"score_spread":0.3503907500403325,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}